LUX Program Examines Pan-HER Inhibitor Afatinib in Multiple Tumor Types
LUX Program Examines Pan-HER Inhibitor Afatinib in Multiple Tumor Types
Filed under: drug treatment programs maryland
Among the studies of afatinib in various tumor types, the drug is in the latest stage of clinical development in non–small cell lung cancer (NSCLC). While other EGFR-targeted therapies have been approved for the treatment of patients with NSCLC …
Read more on OncLive
Tech Council of Maryland Names GlycoMimetics CEO Rachel King as 2013 …
Filed under: drug treatment programs maryland
“The TCM Tech Awards is a prestigious recognition program for technology and life science organizations in Maryland. It is a tremendous honor to be named Executive of the Year,” said Ms. King. “In the ten years since I co-founded GlycoMimetics, I have …
Read more on EON: Enhanced Online News (press release)
SOLIGENIX INC : Soligenix Initiates Phase 1 Clinical Study with SGX203 for the …
Filed under: drug treatment programs maryland
The program has previously received Fast Track and Orphan Drug designations from the U.S. Food and Drug Administration (FDA) for oral BDP as a treatment for pediatric Crohn's Disease. The objective … "There are currently no FDA approved …
Read more on 4-traders (press release)